Your browser doesn't support javascript.
loading
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-ß.
Silk, Jonathan D; Abbott, Rachel J M; Adams, Katherine J; Bennett, Alan D; Brett, Sara; Cornforth, Terri V; Crossland, Katherine L; Figueroa, David J; Jing, Junping; O'Connor, Caitriona; Pachnio, Annette; Patasic, Lea; Peredo, Carlos E; Quattrini, Adriano; Quinn, Laura L; Rust, Alistair G; Saini, Manoj; Sanderson, Joseph P; Steiner, Dylan; Tavano, Barbara; Viswanathan, Preetha; Wiedermann, Guy E; Wong, Ryan; Jakobsen, Bent K; Britten, Cedrik M; Gerry, Andrew B; Brewer, Joanna E.
Afiliación
  • Silk JD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.
  • Abbott RJM; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Adams KJ; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Bennett AD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Brett S; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Cornforth TV; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Crossland KL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Figueroa DJ; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Jing J; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • O'Connor C; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Pachnio A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Patasic L; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Peredo CE; Cell and Gene Therapy Product Development and Supply, Analytical Development, GlaxoSmithKline, Collegeville, PA.
  • Quattrini A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Quinn LL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Rust AG; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Saini M; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Sanderson JP; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Steiner D; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Tavano B; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Viswanathan P; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Wiedermann GE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Wong R; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Jakobsen BK; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Britten CM; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and.
  • Gerry AB; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom.
  • Brewer JE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.
J Immunol ; 208(1): 169-180, 2022 01 01.
Article en En | MEDLINE | ID: mdl-34853077
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Receptores de Antígenos de Linfocitos T / Inmunoterapia Adoptiva / Factor de Crecimiento Transformador beta / Sarcoma Sinovial / Linfocitos T CD8-positivos / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos / Receptor Tipo II de Factor de Crecimiento Transformador beta / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Receptores de Antígenos de Linfocitos T / Inmunoterapia Adoptiva / Factor de Crecimiento Transformador beta / Sarcoma Sinovial / Linfocitos T CD8-positivos / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos / Receptor Tipo II de Factor de Crecimiento Transformador beta / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos